The Goldman Sachs Group Increases GeneDx (NASDAQ:WGS) Price Target to $70.00

GeneDx (NASDAQ:WGSFree Report) had its price target upped by The Goldman Sachs Group from $54.00 to $70.00 in a report published on Wednesday, Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages have also recently weighed in on WGS. BTIG Research lifted their price objective on shares of GeneDx from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. TD Cowen boosted their price target on shares of GeneDx from $46.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Craig Hallum upped their price objective on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $59.33.

Get Our Latest Report on GeneDx

GeneDx Trading Down 1.0 %

Shares of NASDAQ WGS opened at $83.20 on Wednesday. The company has a current ratio of 2.38, a quick ratio of 2.22 and a debt-to-equity ratio of 0.27. The stock has a market capitalization of $2.24 billion, a PE ratio of -26.75 and a beta of 2.32. GeneDx has a twelve month low of $1.16 and a twelve month high of $89.11. The stock has a fifty day simple moving average of $45.65 and a 200-day simple moving average of $32.42.

GeneDx (NASDAQ:WGSGet Free Report) last released its earnings results on Tuesday, July 30th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.15. The company had revenue of $70.51 million during the quarter, compared to the consensus estimate of $58.90 million. GeneDx had a negative return on equity of 22.71% and a negative net margin of 48.21%. On average, equities analysts forecast that GeneDx will post -0.75 earnings per share for the current year.

Insider Buying and Selling at GeneDx

In other news, CFO Kevin Feeley sold 895 shares of GeneDx stock in a transaction on Monday, September 9th. The shares were sold at an average price of $33.33, for a total transaction of $29,830.35. Following the completion of the sale, the chief financial officer now directly owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Katherine Stueland sold 3,639 shares of the stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $121,287.87. Following the transaction, the chief executive officer now owns 95,457 shares in the company, valued at approximately $3,181,581.81. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Feeley sold 895 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $33.33, for a total value of $29,830.35. Following the sale, the chief financial officer now owns 39,910 shares of the company’s stock, valued at approximately $1,330,200.30. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 267,401 shares of company stock valued at $8,794,447. Insiders own 27.30% of the company’s stock.

Institutional Trading of GeneDx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new position in shares of GeneDx in the 2nd quarter valued at $34,000. nVerses Capital LLC purchased a new position in shares of GeneDx during the second quarter worth about $50,000. CWM LLC purchased a new position in shares of GeneDx during the third quarter worth about $89,000. SG Americas Securities LLC acquired a new stake in shares of GeneDx during the third quarter worth about $198,000. Finally, Palumbo Wealth Management LLC purchased a new stake in shares of GeneDx in the 3rd quarter valued at about $287,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

(Get Free Report)

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.

Featured Articles

Analyst Recommendations for GeneDx (NASDAQ:WGS)

Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.